Fate of lymphocytes after withdrawal of tofacitinib treatment

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Piscianz, Elisa ^a   Valencic, Erica ^a   Cuzzoni, Eva ^b   De Iudicibus, Sara ^a   De Lorenzo, Elisa ^c   Decorti, Giuliana ^b   Tommasini, Alberto ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGENIC AGENT; TOFACITINIB;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CELL FATE; CELL FUNCTION; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TIME SERIES ANALYSIS; TREATMENT WITHDRAWAL;

ANTIGENS, CD; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; JANUS KINASE 3; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; PHYTOHEMAGGLUTININS; PIPERIDINES; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84897384127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085463     Document Type: Article

References (21)

1. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, et al. (1994) Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370: 151-153. (Pubitemid 24229128)
2. Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, et al. (1994) Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 91: 6374-6378. (Pubitemid 24200663)
3. O'Shea JJ (2004) Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 63 Suppl 2: ii67-ii71.
4. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, et al. (1995) Defective lymphoid development in mice lacking Jak3. Science 270: 800-802.
5. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, et al. (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270: 797-800.
6. Soto H, Hevezi P, Roth RB, Pahuja A, Alleva D, et al. (2008) Gene array analysis comparison between rat collagen-induced arthritis and human rheumatoid arthritis. Scand J Immunol 68: 43-57. (Pubitemid 351798401)
7. Piscianz E, Cuzzoni E, De Iudicibus S, Valencic E, Decorti G, et al. (2011) Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. Int Immunopharmacol 11: 2242-2245.
8. Kyttaris VC (2012) Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 6: 245-250.
9. Kalluri HV, Hardinger KL (2012) Current state of renal transplant immunosuppression: Present and future. World J Transplant 2: 51-68.
10. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, et al. (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 53: 8468-8484.
11. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, et al. (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 12: 2446-2456.
12. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367: 495-507.
13. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, et al. (2005) Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80: 1283-1292. (Pubitemid 41746807)
14. Conklyn M, Andresen C, Changelian P, Kudlacz E (2004) The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 76: 1248-1255. (Pubitemid 39602962)
15. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, et al. (2009) The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 87: 79-86.
16. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, et al. (1996) Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 157: 4363-4370. (Pubitemid 126449354)
17. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367: 508-519.
18. Vafadari R, Quaedackers ME, Kho MM, Mol WM, Chan G, et al. (2012) Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. Transplantation 94: 465-472.
19. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186: 4234-4243.
20. Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, et al. (2012) Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun 418: 234-240.
21. Egli A, Kumar D, Broscheit C, O'Shea D, Humar A (2013) Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 3: 448-455.